# HanAll Biopharma

HanAll Biopharma is an Asset Manager based in Hwaseong-si, South Korea.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Hwaseong-si, South Korea
- **Region:** Asia
- **Address:** Hwaseong-si, South Korea
- **Assets under management:** Undisclosed
- **Website:** hanall.com
- **LinkedIn:** https://www.linkedin.com/company/hanall

## Regulatory record

- **Reports private funds:** No

## About

HanAll Biopharma develops biopharmaceuticals for autoimmune diseases and oncology using its technology platform. The company serves the pharmaceutical and healthcare industries. Founded in 1973, HanAll Biopharma is based in Seoul, South Korea — formerly known as Seongyeong Pharmaceutical Co., Ltd.

## Sectors

- Healthcare Services

## Offices

- San Francisco, United States
- Seoul, South Korea

## People

- Christopher W Slavinsky — Chief Business Officer

## Questions

### What is the commercial status of the HL161 licensing agreement?

HanAll disclosed receiving a termination notice for the HL161 licensing agreement in a regulatory filing. The company has not publicly detailed the financial impact or the counterparty involved. This leaves a gap in the known royalty revenue projections for that specific program.

### How does HanAll Biopharma generate revenue?

Revenue comes primarily from licensing fees, milestone payments, and royalties on out-licensed drug candidates. The company does not sell therapies directly. Full-year 2025 revenue was 155 billion KRW, driven by double-digit growth in these partnered programs.

### Which therapeutic areas does the pipeline target?

The disclosed pipeline targets autoimmune diseases and neurological disorders. Lead candidate batoclimab addresses a rare disease and has secured Orphan Drug Designation in Japan. The company is also collaborating on epigenetic reprogramming technology for aging-related conditions.

### Where does HanAll Biopharma conduct operations?

The firm is headquartered in Hwaseong-si, South Korea, with an additional office in Seoul. San Francisco serves as its US base, positioning the team to access North American biotech partners and investors.

## Related profiles

- [FreeMind Financial Advisory](https://altss.com/profile/freemind-investments)
- [Detao Capital](https://altss.com/profile/detao-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/hanall-biopharma

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology